Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Cost-effectiveness studies sits at the center of this dementia and brain health question.
Cost-effectiveness studies provide crucial evidence that Alzheimer’s interventions can deliver meaningful value to patients and healthcare systems, though findings vary dramatically depending on how costs are measured and what outcomes count. Recent research demonstrates that some approaches—particularly collaborative care models combining medical and behavioral support—can actually improve patient quality of life while reducing total healthcare costs, a rare outcome in dementia treatment.
For families and physicians facing the complex question of which interventions are worth the investment, these studies offer a framework for understanding not just whether a treatment works, but whether its benefits justify its price in the real world. The landscape of Alzheimer’s economics has shifted substantially with the introduction of disease-modifying therapies like lecanemab, which can slow cognitive decline in early stages but come with price tags that stretch beyond what traditional cost-effectiveness thresholds suggest is affordable. Health economists now grapple with fundamental questions: Should we pay $26,500 annually for a drug that delays decline, or invest that same money in staffing and support services? The answers increasingly depend on who is paying, where they live, and what outcomes they value most.
Table of Contents
- How Do Economic Analyses Measure the Value of Alzheimer’s Interventions?
- Disease-Modifying Therapies and Their Cost-Effectiveness Thresholds
- Collaborative Care Models and Non-Pharmacological Approaches
- Navigating Price, Coverage, and Access in Practice
- Methodological Limitations and When Cost-Effectiveness Studies Mislead
- Geographic Variation in Cost-Effectiveness Determinations
- The Future of Alzheimer’s Economics and Pricing Pressures
- Conclusion
How Do Economic Analyses Measure the Value of Alzheimer’s Interventions?
Cost-effectiveness research translates health benefits into comparable units called quality-adjusted life years (QALYs), which combine survival time with quality of life into a single metric. When a treatment costs $150,000 per QALY gained, it means you’re paying $150,000 for one year of perfect health, adjusted for the limitations that disease imposes. The U.S. healthcare system generally considers interventions cost-effective if they fall below $150,000 per QALY, though this threshold varies by region and payer.
Understanding this framework matters because it determines whether insurance companies will cover a drug, whether Medicare will negotiate its price, and ultimately whether families can access it without devastating financial consequences. A 2024 systematic review examining 23 model-based economic evaluations of dementia interventions revealed significant methodological inconsistencies and reporting gaps across studies, which means some published cost-effectiveness claims should be interpreted cautiously. Researchers modeled future costs and outcomes rather than measuring them in real patients, introducing uncertainty at every step. Disease progression, caregiver burden, and quality-of-life improvements are inherently difficult to predict, and small changes in assumptions can flip a treatment from “cost-effective” to “not cost-effective” entirely. This is why clinicians and families shouldn’t treat a single cost-effectiveness study as definitive—they’re tools for guiding decisions, not absolute truths.
Disease-Modifying Therapies and Their Cost-Effectiveness Thresholds
Disease-modifying therapies like lecanemab are fundamentally different from symptomatic Alzheimer’s drugs because they attempt to slow the underlying disease process rather than temporarily mask symptoms. A novel DMT analyzed in 2024 research showed an incremental cost-effectiveness ratio of $107,000 per QALY from a health sector perspective (counting only direct medical costs) and $74,000 per QALY from a societal perspective (counting lost productivity and caregiver costs). These numbers initially sound reasonable—they fall within or near the $150,000 threshold—but they mask a critical problem: the price of these drugs far exceeds what formal cost-effectiveness analysis suggests is justified. The math becomes stark when you work backward from willingness-to-pay thresholds.
If a drug produces a 30% risk reduction in cognitive decline and we set the threshold at $150,000 per QALY, the maximum cost-effective price is approximately $22,000 per patient annually from a societal perspective or $15,000 annually from a payer-only perspective. Leqembi (lecanemab) launched in the U.S. at $26,500 per year, immediately exceeding the payer threshold and sitting uncomfortably close to the societal ceiling. This pricing creates a genuine bind: the drug may offer real clinical benefit, but its cost means that in strictly economic terms, money spent on lecanemab is money not spent on proven, less expensive interventions like structured caregiver support.
Collaborative Care Models and Non-Pharmacological Approaches
While disease-modifying therapies dominate headlines, research increasingly validates the economic power of collaborative care—combining primary care physicians with behavioral health specialists, care coordinators, and family support. A groundbreaking 2026 study found that collaborative care, compared to usual care, increased quality-adjusted life years by 0.26 per person while generating cost savings of $48,000. This is extraordinarily rare in healthcare: a “dominant” intervention that improves outcomes and reduces cost. The mechanism is straightforward—coordinated care prevents crises, catches complications early, and reduces preventable hospitalizations.
Non-pharmacological interventions like counseling, caregiver training, and structured activity programs cost considerably less than disease-modifying drugs. Monthly costs for individual counseling sessions, caregiver support services, and individualized care planning range from $50 to $160 per care dyad (typically a patient and primary caregiver). Over a year, that’s $600 to $1,920—a fraction of lecanemab’s $26,500 annual cost. The limitation is that these approaches require human time and coordination, which don’t scale as easily as mass-producing a medication. A busy primary care practice might lack the infrastructure to deliver collaborative care, while a patient can receive an infusion at an infusion center with minimal coordination.
Navigating Price, Coverage, and Access in Practice
Healthcare systems, insurers, and individual patients face painful tradeoffs when disease-modifying therapies exceed cost-effectiveness thresholds. Medicare, the U.S. government insurance program covering people over 65, encounters a specific structural barrier: under the Inflation Reduction Act, biologics like lecanemab are exempted from Medicare price negotiations for 13 years following approval.
This means the drug price cannot be directly negotiated down through the largest U.S. insurance program, creating pressure on individuals and supplemental insurance plans to absorb the cost. For patients and families, the practical question is whether they should pursue a disease-modifying therapy even if it falls outside traditional cost-effectiveness ranges. The answer depends on individual circumstances: Are you in early-stage cognitive impairment where the drug shows benefit? Do you have the financial resources or insurance coverage to access it? Are there systemic supports like collaborative care available to augment the drug? A family with significant out-of-pocket costs might reasonably choose to invest in a structured caregiver support program, memory care planning, and respite care rather than a $26,500-per-year drug with modest cognitive benefits, especially knowing that the collaborative care approach has demonstrated cost-effectiveness in rigorous studies.
Methodological Limitations and When Cost-Effectiveness Studies Mislead
The 2024 systematic review documenting quality issues across dementia economic evaluations should prompt healthy skepticism. Many studies used outdated disease progression models, inconsistent outcome measures, and narrow time horizons that failed to capture long-term caregiver burden or informal care costs. A study might show that a drug is cost-effective over two years, but cognitive decline and caregiver exhaustion extend over a decade or more. Additionally, different studies apply different willingness-to-pay thresholds and perspectives—some count only direct medical costs while others include caregiver burden—making direct comparisons difficult.
Another significant limitation: cost-effectiveness studies often exclude or undervalue the quality-of-life gains experienced by family caregivers. When research incorporates caregiver burden into the analysis (the “societal perspective”), cost-effectiveness ratios improve substantially. A disease-modifying therapy that costs $107,000 per QALY from a narrow health-sector view might drop to $74,000 per QALY when caregiver relief is counted. But quantifying caregiver quality of life remains imperfect and contested, so two equally rigorous studies can reach different conclusions based on how they value this component.
Geographic Variation in Cost-Effectiveness Determinations
An important reality often overlooked: whether a treatment is “cost-effective” depends significantly on where you live. Lecanemab provides a clear example. In the United States, analyses conclude it exceeds typical cost-effectiveness thresholds at the $26,500 price point.
But in Canada, the same drug from the same manufacturer at a negotiated price point emerges as cost-effective from a Canadian societal perspective. This isn’t because lecanemab works differently in Canada—it’s because the negotiated Canadian price is lower and Canadian healthcare costs differ. The implication: U.S. patients and payers face a pricing and coverage environment that differs substantially from other developed nations, with potentially important implications for access and fairness.
The Future of Alzheimer’s Economics and Pricing Pressures
The pipeline includes multiple additional disease-modifying therapies (donanemab, aducanumab, and others), each raising the same cost-effectiveness questions. For these drugs to be cost-effective at the $150,000 per QALY threshold with modest efficacy assumptions, pricing would need to be substantially lower than current market prices—aducanumab, for instance, would require pricing below $5,100 per year to be cost-effective. As more disease-modifying options enter the market, payers will inevitably demand price reductions, and the current 13-year Medicare price negotiation exemption for biologics may face political pressure if spending grows dramatically.
The economics of Alzheimer’s care are also shifting as new evidence validates collaborative care models and non-pharmacological approaches. Healthcare systems that can build integrated teams combining geriatricians, neuropsychologists, social workers, and care coordinators may find better value in that infrastructure than in disease-modifying monotherapy. The evidence suggests that the future of cost-effective Alzheimer’s care will likely combine selective use of disease-modifying therapies in eligible patients with robust investments in coordinated care, caregiver support, and evidence-based behavioral interventions.
Conclusion
Cost-effectiveness studies demonstrate that Alzheimer’s interventions offer measurable value, but the data reveals important nuances: collaborative care models deliver both improved outcomes and cost savings, disease-modifying therapies provide clinical benefit but often exceed economic thresholds at current prices, and non-pharmacological approaches deliver substantial value at a fraction of medication costs. The quality of economic evidence is uneven, with significant methodological limitations that suggest adopting conclusions cautiously and comparing multiple studies rather than relying on single analyses.
For patients, families, and healthcare systems, the practical takeaway is that cost-effectiveness isn’t an absolute judgment but a framework for informed decision-making. Geographic variation, insurance status, individual clinical circumstances, and access to different intervention types all shape what is truly “cost-effective” in any given situation. As the dementia treatment landscape evolves, the evidence increasingly points toward integrated, multidisciplinary approaches combining pharmacological and non-pharmacological elements, with pricing pressures likely to reshape which treatments remain economically viable in the coming years.
You Might Also Like
- Insurance Coverage Debates Continue for Alzheimer’s Medications
- Hedge Fund Analysis Examines Alzheimer’s Drug Company Valuations
- Benefit Concerts and Entertainment Events Fund Alzheimer’s Research
For more, see Alzheimer’s Association — clinical trials.
